View Older Stories View More Recent Stories

Jun 2, 2022 07:30AM Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
May 16, 2022 04:15PM Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
Apr 21, 2022 07:30AM Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress
Mar 22, 2022 07:31AM Scholar Rock Holding Corp. (SRRK) Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial
Mar 22, 2022 07:30AM Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting
Mar 13, 2022 07:00PM Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Mar 7, 2022 07:00AM Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress
Feb 25, 2022 07:30AM Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference
Jan 25, 2022 08:30AM Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
Jan 10, 2022 07:38AM Scholar Rock Holding Corp. (SRRK) Provides Corporate Update and Highlights Priorities for 2022
Jan 10, 2022 07:30AM Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
Jan 4, 2022 04:01PM Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference
Nov 30, 2021 04:05PM Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
Nov 12, 2021 07:14AM Scholar Rock Holding Corp. (SRRK) Reports Initial Data from DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors
Nov 12, 2021 07:05AM Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement int
Nov 9, 2021 08:05AM Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress
Nov 2, 2021 04:01PM Scholar Rock to Present at Upcoming Healthcare Conferences
Oct 3, 2021 08:00AM Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
Sep 30, 2021 11:50AM Scholar Rock Holding Corp. (SRRK) Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
Sep 30, 2021 11:45AM Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
Sep 28, 2021 04:04PM Scholar Rock Holding Corp. (SRRK) Announces Issuance of U.S. Patent Protecting SRK-181
Sep 28, 2021 04:01PM  Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation
Sep 23, 2021 11:31AM Scholar Rock Holding Corp. (SRRK) Announces Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial
Sep 23, 2021 11:31AM  Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress
Sep 22, 2021 04:01PM Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference
Aug 16, 2021 04:05PM Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer
Aug 10, 2021 04:15PM Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress
Aug 5, 2021 04:01PM Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference
Aug 3, 2021 07:49AM Scholar Rock Holding Corp. (SRRK) announces CEO Tony Kingsley has departed
Aug 3, 2021 07:30AM Scholar Rock Announces Leadership Change
Jun 18, 2021 08:00AM Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress
Jun 11, 2021 07:32AM Scholar Rock (SRRK) Presents TOPAZ Phase 2 Data Showing Transformative Potential of Apitegromab in Patients with Type 2 and 3 SMA
Jun 11, 2021 07:30AM Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical
Jun 7, 2021 07:30AM Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting
May 27, 2021 08:01AM Scholar Rock to Present at Upcoming Healthcare Conferences in June
May 24, 2021 04:06PM Scholar Rock (SRRK) Receives Fast Track Designation from U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
May 24, 2021 04:05PM Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
May 19, 2021 05:08PM Scholar Rock Holding Corp. (SRRK) to Present Trials in Progress Poster for SRK-181 DRAGON Phase 1 Clinical Trial at the American Society of Clinical Oncology Annual Meeting
May 19, 2021 05:05PM Scholar Rock to Present Trials in Progress Poster for SRK-181 DRAGON Phase 1 Clinical Trial at the American Society of Clinical Oncology Annual Meeting
May 13, 2021 07:30AM Scholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress
May 11, 2021 04:30PM Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy
Apr 26, 2021 04:59PM Scholar Rock (SRRK) Announces Issuance of U.S. Patent Broadly Relevant to Inhibitors of Myostatin Activation
Apr 26, 2021 04:59PM Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Inhibitors of Myostatin Activation
Apr 12, 2021 06:09AM Scholar Rock Holding Corp. (SRRK) Announces Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial
Apr 10, 2021 08:30AM Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual Meeting
Apr 6, 2021 07:09AM Scholar Rock (SRRK) Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 SMA
Apr 6, 2021 07:00AM Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
Mar 22, 2021 04:21PM Scholar Rock (SRRK) Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology
Mar 22, 2021 04:20PM Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology
Mar 18, 2021 04:15PM Scholar Rock Holding Corp. (SRRK) Announces Addition of Joshua Reed to Its Board of Directors
View More Recent Stories View Older Stories